High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.

J Delgado Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by J Delgado in
Current site
Google Scholar
PubMed Close
,
J Macías Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by J Macías in
Current site
Google Scholar
PubMed Close
,
J A Pineda Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by J A Pineda in
Current site
Google Scholar
PubMed Close
,
J E Corzo Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by J E Corzo in
Current site
Google Scholar
PubMed Close
,
M P González-Moreno Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by M P González-Moreno in
Current site
Google Scholar
PubMed Close
,
R de la Rosa Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by R de la Rosa in
Current site
Google Scholar
PubMed Close
,
A Sánchez-Quijano Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by A Sánchez-Quijano in
Current site
Google Scholar
PubMed Close
,
M Leal Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by M Leal in
Current site
Google Scholar
PubMed Close
, and
E Lissen Departamento de Medicina Interna, Hospital Universitario Virgen del Rocío, Seville, Spain.

Search for other papers by E Lissen in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.4269/ajtmh.1999.61.766
Volume/Issue:
Volume 61: Issue 5
Page(s):
766–769
Restricted access
Get Permissions

Organic pentavalent antimonials are one of the mainstays of treatment for visceral leishmaniasis (VL). Few data are available on the toxicity and efficacy of these drugs at the dosing schedule recommended by the Centers for Disease Control and Prevention (CDC) (Atlanta, GA). We analyzed 25 VL episodes in human immunodeficiency virus (HIV)-infected patients who were treated with meglumine antimoniate (MA) at the CDC-recommended dose in southern Spain. Adverse effects were observed in 14 (56%) VL episodes. In 7 (28%), treatment with MA was permanently discontinued due to serious adverse effects that included acute pancreatitis, acute renal failure, and leukopenia. Three (12%) patients died during therapy due to severe acute pancreatitis attributable to MA. The dosing regimen of MA currently recommended for treating VL is associated with a high rate of serious side effects in HIV-1-infected patients.

Published Online:
Nov 1999
Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
Past two years Past Year Past 30 Days
Abstract Views 214 196 15
Full Text Views 205 4 0
PDF Downloads 71 7 0
 
Membership Banner
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save